Exploratory health economic analyses to support decisions within the innovation process in radiotherapy: Magnetic Resonance Linear Accelerator as a case study
Background and purpose: There is an increasing need for understanding the added value of radiotherapeutic innovations before their widespread adoption. For multi-purpose innovations such as the Magnetic Resonance Linear Accelerator (MR-Linac), determining their value within a specific clinical conte...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-06-01
|
| Series: | Technical Innovations & Patient Support in Radiation Oncology |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2405632425000150 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Background and purpose: There is an increasing need for understanding the added value of radiotherapeutic innovations before their widespread adoption. For multi-purpose innovations such as the Magnetic Resonance Linear Accelerator (MR-Linac), determining their value within a specific clinical context does not conclusively answer the broader question whether the innovation justifies the required investment. Exploratory analyses can be informative during early development and use of the innovation. We aim to develop and demonstrate an online, flexible tool to facilitate early economic evaluation of the MR-Linac. Materials and methods: We developed a tool that enables users to compare the total costs and incremental effects needed of MRI-guided radiotherapy (MRIgRT) with conventional treatment by inputting data specific to their context. Costs included in the tool are both medical technology and personnel-related expenses. The effects, required to justify potential additional costs, are expressed in Quality Adjusted Life Years (QALYs). By default, input values are used tailored to the Dutch clinical context. Results: When users input data specific to their context or situation, the tool generates figures that display the (additional) costs and effects of MRIgRT compared to conventional treatment. These figures enable users to explore the impact of key variables on the (additional) costs and QALYs required to justify any potential extra costs associated with MRIgRT. Conclusion: The tool and accompanying example allow for exploratory early HTA analyses, which can offer insights into the cost-effectiveness of MRIgRT. These insights can be valuable for guiding decisions regarding the purchase and utilization of innovative radiotherapeutic technologies. |
|---|---|
| ISSN: | 2405-6324 |